Last reviewed · How we verify

NCT03442296: HEARS

Baltimore HEARS: Hearing Health Equity Through Accessible Research & Solutions

Completed NA Results posted Last updated 4 October 2022
What this trial tests

NA trial testing Baltimore HEARS in Age-related Hearing Impairment 1 in 151 participants. Completed in 14 July 2021.

Timeline
18 April 2018
Primary endpoint
17 June 2020
14 July 2021

Quick facts

Lead sponsorJohns Hopkins University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment151
Start date18 April 2018
Primary completion17 June 2020
Estimated completion14 July 2021
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Johns Hopkins University

Who can join

Adults 60 to 100, any sex, with Age-related Hearing Impairment 1 or Personal Communication. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Hearing Handicap Inventory for the Elderly (HHIE-S) Primary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

Measure was collected through a one-on-one interview with a trained data collector. Higher scores indicate increased hearing handicap. Scoring: 0-8 suggests no hearing handicap 10-24 suggests mild-moderate hearing handicap 26-40 suggests significant hearing handicap Change from baseline is reported. An increase in the score from baseline (a positive number) indicates a worsening in hearing handicap.

GroupValue95% CI
Immediate Treatment Group-13.2± 10.3
Delayed Treatment Group.06± 7.1
Change From Baseline in Revised UCLA Loneliness Scale Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

Measure was collected via a one-on-one interview conducted by a trained data collector. Score is the sum of 20-item self-reported measure. Scores range from 20 to 80. Score ranges: 20-34 - Low degree of loneliness 35-49 - Moderate degree of loneliness 50-64 - Moderately high degree of loneliness 65-80 - High degree of loneliness. Change from baseline is reported. An increase in the score from baseline (a positive number) indicates a worsening in degree of loneliness.

GroupValue95% CI
Immediate Treatment Group-2.8± 8.7
Delayed Treatment Group-0.6± 7
Change From Baseline in Self-reported Depression in Patient Health Questionnaire (PHQ-9) Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

Measure collected via one-on-one interview conducted by trained data collectors. Total of 9 questions, scored from 0 to 3. The score from each question are summed to a total score, which can range from 0 to 27. Interpretation of Total Score Total Score Depression Severity 0 No depression 1-4 Minimal depression 5-9 Mild depression 10-14 Moderate depression 15-19 Moderately severe depression 20-27 Severe depression. Change from baseline is reported. An increase in the score from baseline (a positive number) indicates a worsening in depression severity.

GroupValue95% CI
Immediate Treatment Group-1± 4.3
Delayed Treatment Group-0.2± 4
Change From Baseline in Short Form-12 (SF-12) Mental Component Score Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

The 12-Item Short Form Survey (SF-12) was collected through a one-on-one interview with a trained data collector. The 12-Item Short Form Survey (SF-12) measures the construct of self-reported health-related quality of life. Here we report the mental component which relates to mental health functioning. Score ranges from 0-100 with higher scores indicating better mental health functioning. Change from baseline is reported. An increase in the score from baseline (a positive number) indicates a better health state.

GroupValue95% CI
Immediate Treatment Group1.1± 11.2
Delayed Treatment Group-1.4± 10
Change From Baseline in Short Form -12 (SF-12) Physical Component Score Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

The 12-Item Short Form Survey (SF-12) was collected through a one-on-one interview with a trained data collector. The 12-Item Short Form Survey (SF-12) measures the construct of self-reported health-related quality of life. Here we report the physical component which relates to physical health functioning. Score ranges from 0-100 with higher scores indicating better physical health functioning. Change from baseline is reported. An increase in the score from baseline (a positive number) indicates a better health state.

GroupValue95% CI
Immediate Treatment Group4.4± 10.4
Delayed Treatment Group-0.4± 10.1
Change From Baseline in Cohen Social Network Index (SNI): Network Diversity Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

Change from baseline in total number of high contact roles the participant interacts with at least every 2 weeks (such as family, friends, work). Maximum of 12 roles included on the measure. An increase in the score from baseline (a positive number) indicates a more diverse network.

GroupValue95% CI
Immediate Treatment Group0.3± 1.2
Delayed Treatment Group-0.0± 1.2
Change From Baseline in Cohen Social Network Index (SNI): Social Network Size Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

Change from baseline in total number of individuals in high contact roles the participant interacts with at least every 2 weeks (such as family, friends, work). .An increase in the number of individuals from baseline (a positive number) indicates an increase in their social network size.

GroupValue95% CI
Immediate Treatment Group1.8± 10.5
Delayed Treatment Group1.0± 7.2
Change From Baseline in Valuation of Life Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

This self-reported 13 question measure asks the participant how much they agree or disagree on a 5 point Likert scale when asked a statement about the meaning of life and personal goals. Score ranges from 0 to 65. Higher score means higher value of life. Change from baseline score is reported. An increase in the score from baseline (a positive number) indicates a higher value of life.

GroupValue95% CI
Immediate Treatment Group0.1± 6.9
Delayed Treatment Group-0.6± 5.1
Change From Baseline in Adapted From Attitudes Towards Computers Questionnaire (ATCQ): Computer Self-Efficacy Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

A 5 question measure surveying self-reported self-efficacy of computer use on a 5 point Likert scale. Score ranges from 0 to 25. Change from baseline score is reported. An increase in the score from baseline (a positive number) indicates a higher self-efficacy.

GroupValue95% CI
Immediate Treatment Group-0.5± 3.8
Delayed Treatment Group0± 3.2
Change From Baseline in Adapted From Attitudes Towards Computers Questionnaire (ATCQ): Device Self-Efficacy Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

A 5 question measure surveying self-reported device self-efficacy on a 5 point Likert scale. Score ranges from 0 to 25. Change from baseline score is reported. An increase in the score from baseline (a positive number) indicates a higher self-efficacy.

GroupValue95% CI
Immediate Treatment Group-0.6± 3.8
Delayed Treatment Group-0.1± 3.6
Change From Baseline in Adapted From Attitudes Towards Computers Questionnaire (ATCQ): Listening Device Interest Secondary · Baseline and 3 months post-intervention (Immediate Group) or 3 months post-baseline (Delayed Group)

A 5 question measure surveying self-reported self-efficacy of listening device interest on a 5 point Likert scale. Score ranges from 0 to 25. Change from baseline score is reported. An increase in the score from baseline (a positive number) indicates a higher self-efficacy.

GroupValue95% CI
Immediate Treatment Group0.7± 2.3
Delayed Treatment Group-0.4± 2.5
Change From Baseline in Adapted From Listening Self-Efficacy Questionnaire (LSEQ): Total Score Secondary · Baseline and 3 month post-intervention (immediate group) or 3 month post-baseline (delayed group)

This 5 question survey measures listening self efficacy on a 0-10 scale in different situations such as being able to understand a conversation in a quiet room to a crowded restaurant. Participants answer with a higher number the more confident they are in the presented situation. Maximum possible score is 50. Change from baseline score is reported. An increase in the score from baseline (a positive number) indicates a higher self-efficacy.

GroupValue95% CI
Immediate Treatment Group10.8± 11.3
Delayed Treatment Group-0.7± 8.1

Sponsor's own description

Age-related hearing loss is highly prevalent and hearing health care is underutilized. The primary objective of the proposed randomized controlled trial is to investigate the efficacy of a community health worker (CHW)-delivered hearing loss intervention program. A preceding pilot study demonstrated preliminary effectiveness of the intervention program in reducing self-reported hearing handicap, and highlighted its acceptability among the target demographic. The proposed trial will now expand upon lessons learned through previous pilot studies and expand to other affordable residences for low-to-moderate income older adults in Baltimore. Primary outcome measurements will investigate intervention effects on hearing handicap, with secondary measurements investigating effects on domains such as social isolation and quality of life. This trial is a first-in-kind investigation of a novel community-based intervention that addresses hearing loss in a vulnerable, urban population.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Community-Based Participatory Research and Human-Centered Design Principles to Advance Hearing Health Equity.
    Marrone NL, Nieman CL, Coco L. · · 2022 · cited 30× · PMID 35724253 · DOI 10.1097/aud.0000000000001183
  2. Hearing care across the life course provided in the community.
    Suen JJ, Bhatnagar K, Emmett SD, Marrone N, et al · · 2019 · cited 30× · PMID 31656333 · DOI 10.2471/blt.18.227371
  3. Translating Public Health Practices: Community-Based Approaches for Addressing Hearing Health Care Disparities.
    Suen JJ, Marrone N, Han HR, Lin FR, et al · · 2019 · cited 25× · PMID 30728648 · DOI 10.1055/s-0038-1676782
  4. Effect of a Community Health Worker-Delivered Personal Sound Amplification Device on Self-Perceived Communication Function in Older Adults With Hearing Loss: A Randomized Clinical Trial.
    Nieman CL, Betz J, Garcia Morales EE, Suen JJ, et al · · 2022 · cited 24× · PMID 36538311 · DOI 10.1001/jama.2022.21820
  5. A Community Health Worker Training Program to Deliver Accessible and Affordable Hearing Care to Older Adults.
    Suen JJ, Han HR, Peoples CY, Weikert M, et al · · 2021 · cited 9× · PMID 33678679 · DOI 10.1353/hpu.2021.0006
  6. Program Abstracts from The GSA 2021 Annual Scientific Meeting, "Disruption to Transformation: Aging in the "New Normal"".
    · 2021 · cited 1× · PMID 34926835 · DOI 10.1093/geroni/igab046
  7. Recruitment and Retention in Diverse Cohorts: Lessons From Community-Engaged Efforts
    · 2021
  8. Community-Engaged Strategies for Recruitment of Korean Americans in Community-Based Research Studies
    Han H, Lee H, Kim M. · · 2021

Verify or expand the search:

Other Johns Hopkins University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03442296.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing